Intranasal sodium cromoglycate in post-catarrhal hyperreactive rhinosinusitis: a double-blind placebo controlled trial.
A randomized double-blind comparison was made between sodium cromoglycate and a placebo (saline) given as nasal sprays, to control symptoms of post-catarrhal hyperreactive rhinosinusitis. No significant differences were demonstrated between the two test treatments in rhinopharyngeal symptoms, ultrasonic scannings of mucosal thickness in the maxillary sinus, or in the patients' evaluation of rhinitic symptoms. There was an improvement in symptoms in about 50% of the patients in each treatment group.
Sederberg-Olsen
J F
JF
E.N.T. Clinic, Helsingøor, Denmark.
Sederberg-Olsen
A E
AE
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003139:Common Cold / Q000150:complications; D004205:Cromolyn Sodium / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009330:Nebulizers and Vaporizers; D016032:Randomized Controlled Trials as Topic; D012220:Rhinitis / Q000188:drug therapy*; D012852:Sinusitis / Q000188:drug therapy*
D004205:Cromolyn Sodium